A qualitative study of patient experience when switching from paliperidone palmitate once monthly (PP1M) to paliperidone palmitate three monthly (PP3M) long-acting injectable antipsychotic (original) (raw)

This qualitative study explores patient experiences when switching from paliperidone palmitate once monthly (PP1M) to paliperidone palmitate three monthly (PP3M). Fourteen patients diagnosed with schizophrenia or schizoaffective disorder participated, reviewing their perceptions before and after the transition. Findings indicate that the majority of patients reported no significant differences post-switch, with mild side effects, and a general preference for the less frequent injection of PP3M. Overall feelings towards long-acting injectables were positive, noting convenience and satisfaction with the change.